Immunohistochemical analysis of p53 protein in uterine sarcomas

Gynecologic Oncology

Volumn 70, Issue 1, 1998, Pages 45-48

  Nordal, Randi R ^a   Kristensen, Gunnar B ^a   Stenwig, Anne Elisabeth ^a   Tropé, Claes G ^a   Nesland, Jahn M ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; DNA; MONOCLONAL ANTIBODY; PROTEIN P53;

ADULT; AGED; ANTIGEN RETRIEVAL; ARTICLE; CANCER SURVIVAL; CARCINOGENESIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MICROSCOPY; MICROWAVE OVEN; MITOSIS; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; UTERUS SARCOMA;

EID: 0032126042     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1998.5034     Document Type: Article

References (38)

1. Hollstein M, Sidransky D, Vogelstein B, Harris C C. p53 mutations in human cancers. Science. 253:1991;49-53.
2. Rotter V, Prokocimer M. p53 and human malignancies. Adv Cancer Res. 57:1991;257-272.
3. Thor A D, Moore D H II, Edgerton S M, Kawasaki E S, Reihsaus E, Lynch H T, Marcus J N, Schwartz L, Chen L C, Mayall B H. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst. 84:1992;845-855.
4. Malkin D, Li F P, Strong L C, Fraumeni J F Jr, Nelson C E, Kim D H, Kassel J, Gryka M A, Bischoff F Z, Tainsky M A. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science. 250:1990;1233-1238.
5. Nigro J M, Baker S J, Preisinger A C, Jessup J M, Hostetter R, Cleary K, Bigner S H, Davidson N, Baylin S, Devilee P. Mutations in the p53 gene occur in diverse human tumour types. Nature. 342:1989;705-708.
6. Okamoto A, Sameshima Y, Yamada Y, Teshima S, Terashima Y, Terada M, Yokota J. Allelic loss on chromosome 17p and p53 mutations in human endometrial carcinoma of the uterus. Cancer Res. 51:1991;5632-5635.
7. Bosari S, Viale G, Radaelli U, Bossi P, Bonoldi E, Coggi G. p53 accumulation in ovarian carcinomas and its prognostic implications. Hum Pathol. 24:1993;1175-1179.
8. Bur M E, Perlman C, Edelmann L, Fey E, Rose P G. p53 expression in neoplasms of the uterine corpus. Am J Clin Pathol. 98:1992;81-87.
9. Quinlan D C, Davidson A G, Summers C L, Warden H E, Doshi H M. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res. 52:1992;4828-4831.
10. Andreassen A, Oyjord T, Hovig E, Holm R, Florenes V A, Nesland J M, Myklebost O, Hoie J, Bruland O S, Borresen A L. p53 abnormalities in different subtypes of human sarcomas. Cancer Res. 53:1993;468-471.
11. Liu F S, Kohler M F, Marks J R, Bast R C Jr, Boyd J, Berchuck A. Mutation and overexpression of the p53 tumor suppressor gene frequently occurs in uterine and ovarian sarcomas. Obstet Gynecol. 83:1994;118-124.
12. Harris C C, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med. 329:1993;1318-1327.
13. Bosari S, Viale G. The clinical significance of p53 aberrations in human tumours. Virchows Arch. 427:1995;229-241.
14. Silvestrini R, Benini E, Daidone M G, Veneroni S, Boracchi P, Cappelletti V, Di Fronzo G, Veronesi U. p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst. 85:1993;965-970.
15. Ostrowski J L, Sawan A, Henry L, Wright C, Henry J A, Hennessy C, Lennard T J, Angus B, Horne C H. p53 expression in human breast cancer related to survival and prognostic factors: an immunohistochemical study. J Pathol. 164:1991;75-81.
16. Zheng W, Cao P, Zheng M, Kramer E E, Godwin T A. p53 overexpression and bcl-2 persistence in endometrial carcinoma: Comparison of papillary serous and endometrioid subtypes. Gynecol Oncol. 61:1996;167-174.
17. Kihana T, Hamada K, Inoue Y, Yano N, Iketani H, Murao S, Ukita M, Matsuura S. Mutation and allelic loss of the p53 gene in endometrial carcinoma: Incidence and outcome in 92 surgical patients. Cancer. 76:1995;72-78.
18. Ito K, Watanabe K, Nasim S, Sasano H, Sato S, Yajima A, Silverberg S G, Garrett C T. Prognostic significance of p53 overexpression in endometrial cancer. Cancer Res. 54:1994;4667-4670.
19. Geisler J P, Wiemann M C, Zhou Z, Miller G A, Geisler H E. p53 as a prognostic indicator in endometrial cancer. Gynecol Oncol. 61:1996;245-248.
20. Scully, R, E, Bonfiglio, T, A, Kurman, R, J, Silverberg, S, G, Wilkinson, E, J, Histological Typing of Female Genital Tract Tumours, Berlin, Springer-Verlag, 1994.
21. Angervall L, Kindblom L G. Principles for the pathologic diagnosis of soft tissue sarcomas. Acta Oncol. 28:1989;9-17.
22. Nordal R R, Kjorstad K E, Stenwig A E, Trope C G. Leiomyosarcoma (LMS) and endometrial stromal sarcoma (ESS) of the uterus: A survey of patients treated in the Norwegian Radium Hospital 1976-1985. Int J Gynecol Cancer. 3:1993;110-115.
23. Nordal R R, Kristensen G B, Kaern J, Stenwig A E, Petterson E O, Trope C G. The prognostic significance of stage, tumor size, cellular atypia and DNA ploidy in uterine leiomyosarcoma. Acta Oncol. 34:1995;797-802.
24. Nordal R R, Kristensen G B, Kaern J, Stenwig A E, Pettersen E O, Trope C G. The prognostic significance of surgery, tumor size, malignancy grade, menopausal status, and DNA ploidy in endometrial stromal sarcoma. Gynecol Oncol. 62:1996;254-259.
25. Nordal R R, Thoresen S. Uterine sarcomas in Norway 1956-1992: Incidence, survival and mortality. Eur J Cancer. 33:1997;907-911.
26. Hsu S M, Raine L, Fanger H. A comparative study of the peroxidase-antiperoxidase method and an avidin-biotin complex method for studying polypeptide hormones with radioimmunoassay antibodies. Am J Clin Pathol. 75:1981;734-738.
27. Kaplan E L, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481.
28. Cox D R. Regression models and life tables. J R Stat Soc London B. 34:1972;187-220.
29. Stratton M R, Moss S, Warren W, Patterson H, Clark J, Fisher C, Fletcher C D, Ball A, Thomas M, Gusterson B A. Mutation of the p53 gene in human soft tissue sarcomas: Association with abnormalities of the RB1 gene. Oncogene. 5:1990;1297-1301.
30. Christopherson W M, Williamson E O, Gray L A. Leiomyosarcoma of the uterus. Cancer. 29:1972;1512-1517.
31. Norris H J, Taylor H B. Postirradiation sarcomas of the uterus. Obstet Gynecol. 26:1965;689-694.
32. Rodriguez J, Hart W R. Endometrial cancers occurring 10 or more years after pelvic irradiation for carcinoma. Int J Gynecol Pathol. 1:1982;135-144.
33. Meredith R F, Eisert D R, Kaka Z, Hodgson S E, Johnston G A Jr, Boutselis J G. An excess of uterine sarcomas after pelvic irradiation. Cancer. 58:1986;2003-2007.
34. Li F P, Cassady J R, Jaffe N. Risk of second tumors in survivors of childhood cancer. Cancer. 35:1975;1230-1235.
35. Tucker M A, Coleman C N, Cox R S, Varghese A, Rosenberg S A. Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med. 318:1988;76-81.
36. Brachman D G, Hallahan D E, Beckett M A, Yandell D W, Weichselbaum R R. p53 gene mutations and abnormal retinoblastoma protein in radiation-induced human sarcomas. Cancer Res. 51:1991;6393-6396.
37. Reinhold D S, Walicka M, Elkassaby M, Milam L D, Kohler S K, Dunstan R W, McCormick J J. Malignant transformation of human fibroblasts by ionizing radiation. Int J Radiat Biol. 69:1996;707-715.
38. Lee J M, Abrahamson J L, Kandel R, Donehower L A, Bernstein A. Susceptibility to radiation-carcinogenis and accumulation of chromosomal breakage in p53 deficient mice. Oncogene. 9:1994;3731-3736.